492 related articles for article (PubMed ID: 23850487)
1. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
2. Preparation of [
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
[TBL] [Abstract][Full Text] [Related]
3. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
4. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
5. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
[TBL] [Abstract][Full Text] [Related]
6. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
7. The practicality of nanoceria-PAN-based (68)Ge/(68)Ga generator toward preparation of (68)Ga-labeled cyclic RGD dimer as a potential PET radiotracer for tumor imaging.
Chakraborty S; Chakravarty R; Sarma HD; Dash A; Pillai MR
Cancer Biother Radiopharm; 2013 Feb; 28(1):77-83. PubMed ID: 22967229
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
[TBL] [Abstract][Full Text] [Related]
9. Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Balkin ER; Liu D; Jia F; Ruthengael VC; Shaffer SM; Miller WH; Lewis MR
Nucl Med Biol; 2014 Jan; 41(1):36-42. PubMed ID: 24267052
[TBL] [Abstract][Full Text] [Related]
10. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.
Shi J; Kim YS; Zhai S; Liu Z; Chen X; Liu S
Bioconjug Chem; 2009 Apr; 20(4):750-9. PubMed ID: 19320477
[TBL] [Abstract][Full Text] [Related]
11. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
[TBL] [Abstract][Full Text] [Related]
13. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
14. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
[TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer.
Shi J; Liu Z; Jia B; Yu Z; Zhao H; Wang F
Amino Acids; 2010 Jun; 39(1):111-20. PubMed ID: 19941017
[TBL] [Abstract][Full Text] [Related]
16. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
Das T; Chakraborty S; Banerjee S; Venkatesh M
Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
[TBL] [Abstract][Full Text] [Related]
17. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
18. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
19. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
